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The objective of this study was a comprehensive analysis of the immune-driven evolution of viruses of human
immunodeficiency virus type 1 (HIV-1) clade B in a large patient cohort treated at a single hospital in Germany
and its implications for antiretroviral therapy. We examined the association of the HLA-A, HLA-B, and
HLA-DRB1 alleles with the emergence of mutations in the complete protease gene and the first 330 codons of
the reverse transcriptase (RT) gene of HIV-1, studying their distribution and persistence and their impact on
antiviral drug therapy. The clinical data for 179 HIV-infected patients, the results of HLA genotyping, and
virus sequences were analyzed using a variety of statistical approaches. We describe new HLA-associated
mutations in both viral protease and RT, several of which are associated with HLA-DRB1. The mutations
reported are remarkably persistent within our cohort, developing more slowly in a minority of patients.
Interestingly, several HLA-associated mutations occur at the same positions as drug resistance mutations in
patient viruses, where the viral sequence was acquired before exposure to these drugs. The influence of HLA
on thymidine analogue mutation pathways was not observed. We were able to confirm immune-driven selection
pressure by major histocompatibility complex (MHC) class I and II alleles through the identification of
HLA-associated mutations. HLA-B alleles were involved in more associations (68%) than either HLA-A (23%)
or HLA-DRB1 (9%). As several of the HLA-associated mutations lie at positions associated with drug resis-
tance, our results indicate possible negative effects of HLA genotypes on the development of HIV-1 drug
resistance.
Human immunodeficiency virus (HIV) infection has become
a major global human health issue, with more than 39 million
people infected worldwide and 2.9 million AIDS-related
deaths in 2006 alone (32). A major challenge to natural or
vaccine-induced immune control of HIV is the ability of the
virus to mutate rapidly when it comes under pressure from the
host’s immune system (4, 8, 15, 26). Antiviral cytotoxic T lym-
phocytes (CTLs) kill HIV-infected cells upon the recognition
of specific viral epitopes. HIV type 1 (HIV-1) escape mutations
interfere with the processing of viral antigens by proteasomes
(2, 33, 34) or evolve at critical binding sites within the human
leukocyte antigen (HLA)-restricted CTL epitope, thereby ab-
rogating binding to the HLA molecule or inhibiting efficient
recognition by the T-cell receptor (13, 28). Thus, HIV escapes
antiviral immune responses and eradication by the host’s im-
mune system. Such selection pressure as well as viral adapta-
tion to antiretroviral drugs should lead to consistent changes in
the amino acid sequence of the dominant population of the
viral quasispecies.
Recently, Moore et al. studied the selection pressure exerted
by HLA-restricted immune responses on the evolution of the
HIV-1 sequence at the population level (30). A cohort of 473
HIV-1-infected patients was genotyped for the HLA-A and
HLA-B loci. The most recent sequence of the HIV-1 reverse
transcriptase (RT) between amino acid positions 20 and 227
was aligned to an HIV-1 consensus sequence, and viral muta-
tions were identified. These mutations were then tested for
association with distinct HLA-A or -B alleles. The authors
identified 64 positive and 17 negative associations, although
only 12 remained after correction for multiple testing. Several
of these mutations were located in known CTL epitopes.
In a second study of the same cohort, the aforementioned
group identified interactions between antiretroviral drugs and
HLA alleles and diversity in the RT and protease viral se-
quences (21). These interactions led to higher frequencies of
antiviral drug resistance mutations in patients with certain
HLA alleles in some cases but also to lower frequencies in
other cases. This indicates that HLA-dependent specific im-
mune responses can support but also prevent the evolution of
drug resistance.
* Corresponding author. Mailing address: Medizinische Klinik 1,
Universita¨tskliniken Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn,
Germany. Phone: 49 228 2876789. Fax: 49 228 2879822. E-mail: ulrich
.spengler@ukb.uni-bonn.de.
† Both authors contributed equally to this work.
 Published ahead of print on 22 August 2007.
1266
The previous studies have analyzed the HLA-driven evolu-
tion of HIV-1 in only a fragment of the RT and protease.
Therefore we wanted to examine if this phenomenon can be
confirmed in the entire first half of the RT. We were also
interested in extending the analysis to include the major his-
tocompatibility complex (MHC) class II locus HLA-DRB1 to
better understand selection pressure by CD4 T helper cells at
the population level. In order to minimize the influence of
founder effects on the HLA associations found (7), we limited
the analysis to only those patients infected by HIV-1 clade B
viruses and performed an analysis of potential viral linage
effects within the cohort.
Furthermore, we wanted to assess the presence of “hot
spots,” where the sequence mutates more easily/rapidly due to
immune pressure, and how mutations persist over time.
Finally, to understand the clinical significance of our find-
ings, we analyzed whether HLA-driven mutations in the RT
and/or protease sequence of HIV-1 lead to antiviral drug re-
sistance and if a patient’s HLA type has an impact on whether
drug resistance mutations are accumulated in a specific order
in the case of thymidine analogue mutations (TAMs).
MATERIALS AND METHODS
Patients. We studied 179 clade B HIV-1-positive patients being treated at a
single hospital in Bonn, Germany. The patients were monitored every 3 months,
and any complications were recorded and classified according to the European
modification of the 1986 Centers for Disease Control and Prevention staging
(11). Antiviral therapy was advised according to updated recommendations on
antiretroviral treatment for HIV infection from the relevant International AIDS
Society panel. HIV-1 sequence data were collected between March 1999 and
May 2003, with some patients having sequences collected at more than one time
point. Additional information on HIV transmission, ethnicity, sex, and hepatitis
B virus (HBV) and HCV infection status was also acquired (Table 1).
HLA genotyping was performed using the INNO-LiPA line probe assays from
Innogenetics for HLA-A, HLA-B (MHC class I loci), and HLA-DRB1 (MHC
class II locus) according to the manufacturer’s instructions. These are assays
based on the reverse hybridization principle (12). Ambiguous results were fur-
ther resolved by strand-specific PCR (One Lambda, Canoga Park, CA).
For HIV genotyping, a fragment of the pol gene containing the complete
protease gene and the first 650 to 750 nucleotides of the RT gene was
analyzed by direct sequencing of PCR products, as described in the work of
Balduin et al. (3).
All patient and sequence information was entered into a relational database
specifically designed for the analysis of the host immune response effects in
HIV-1 infection.
HLA-associated mutations in the RT and protease. All amino acids in the
complete protease and between positions 1 and 330 in the RT were examined in
the most recent sequences from all patients. As a first step, we analyzed each
amino acid position by use of an extension of Fisher’s exact test for associations
with HLA alleles (29). In order to improve the power of the calculations, very
rare alleles (less than or equal to 4% of the cohort) were excluded from the
analysis. All HLA allele covariates with P values of less than 0.05 were identified
and fitted in a subsequent multivariate analysis to logistic regression models. We
used binomial models where the linear predictor consisted of all significant
alleles and the response was a factor for which variant amino acids were classified
as successes. Correction for multiple testing used the false discovery rate (FDR)
method (6). Due to the low numbers of deletions and insertions in the sequences,
no separate analysis was done to take these into account.
Distribution and persistence of HLA-associated mutations. A previous study
has described CTL epitope “hot spots,” in which immunodominant epitopes
cluster within distinct regions of the HIV gp120 protein (9). The CTL epitopes
collected in the HIV Molecular Immunology Database at Los Alamos also
appeared to be localized in particular regions of HIV proteins (27). We were
interested in determining whether the distribution of HLA-associated mutations
was uniform across the RT and protease. Therefore, the distribution of known
mutations was compared to 10,000 randomly generated distributions according
to the uniform model, each with an equal number of sequence mutations, and
tested for statistical significance.
We also analyzed the persistence of HLA-associated mutations over time in
our cohort. For 70 patients, HIV sequences were available for at least two
individual time points that were a minimum of 6 months apart (the sequences for
50 patients were collected more than 1 year apart). None of these sequences was
acquired during the acute stage of HIV infection; rather, they were acquired at
a later time point. The persistence of mutations was examined at each of the
already identified positions.
Impact of HLA on drug resistance mutation pathways. During antiretroviral
therapy, the virus is exposed to strong selective pressure, which can result in an
accumulation of mutations conferring drug resistance. These mutations are usu-
ally persistent, provided that there is continuous drug-induced selection pressure
(31). Therefore, the development of resistance within the HIV genome can be
regarded as the accumulation of such mutations. This accumulation has been
modeled by weighted branchings or directed trees, which provide an intuitive
model of directed dependencies between events and their time of occurrence.
The single-tree model has been extended to mixtures of trees (so-called mutage-
netic tree mixture models) in order to capture more complex evolutionary sce-
narios, for which the software package Mtreemix has been developed (5).
Of particular interest were the TAMs in the RT that can arise after treatment
with nucleoside RT inhibitors (NRTIs) zidovudine, stavudine, and abacavir.
Studies have suggested that HIV-1 develops TAMs by one of two distinct path-
ways: TAM1 (41L, 210W, and 215F/Y) or TAM2 (67N, 70R, and 219E/Q) (17).
We identified all patients in our cohort that had undergone NRTI treatment
and examined their HIV sequences for TAMs to determine whether particular
HLA alleles can be associated with either the TAM1 or the TAM2 pathway.
HLA-driven selection at antiretroviral drug resistance sites. Several HLA
allele-specific mutations have been reported to be located in positions of known
drug resistance mutations (21, 22). An analysis of the sequences of our patient
TABLE 1. Characteristics of the patient cohort
Parametera Valueb
Total patients (no.) ....................................................................179
Age (yr)
Average.................................................................................... 42
Range....................................................................................... 22–70
Sex (no. of females/no. of males)............................................. 15/164
Ethnicity
Caucasian ................................................................................161 (90.0)
Other........................................................................................ 13 (7.3)
Unknown ................................................................................. 5 (2.7)
Risk code
Homosexual ............................................................................ 99 (55.3)
Heterosexual ........................................................................... 12 (6.7)
i.v. drug abuse......................................................................... 12 (6.7)
Residency in region of epidemicity...................................... 3 (1.7)
Exposure to blood products.................................................. 1 (0.5)
Hemophilia.............................................................................. 40 (22.3)
Unknown ................................................................................. 12 (6.7)
HIV-1 viral subtype
B ...............................................................................................179 (100)
Chronic HCV infection ............................................................. 55 (30.7)
HCV genotype
1................................................................................................ 29 (16.2)
2 ................................................................................................ 8 (4.5)
3 ................................................................................................ 10 (5.6)
4 ................................................................................................ 2 (1.1)
Multiple ................................................................................... 1 (0.5)
Unknown ................................................................................. 5 (2.7)
HBV status
HBs ....................................................................................... 15 (8.4)
Anti-HBs, anti-HBc......................................................... 23 (12.8)
Anti-HBs, Anti-HBc........................................................ 45 (25.1)
Anti-HIV therapy status
Naive ........................................................................................ 14 (7.8)
ART (3 antiviral drugs) ..................................................... 18 (10.1)
HAART (3 antiviral drugs) ...............................................147 (82.1)
a i.v., intravenous; ART, antiretroviral therapy.
b Unless otherwise indicated, values are numbers (percentages) of patients.
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cohort was performed in order to determine whether similar associations could
be identified.
Phylogenetic analysis. In order to explore the impact of viral lineage founder
effects, we applied ProtTest version 1.3 (1, 14, 16) to find the best-fitting model
of protein evolution for the HIV sequence alignment of the cohort. The best-
fitting model according to both the Akaike information criterion and the Bayes-
ian information criterion (19) was the Jones-Taylor-Thornton (JTT) model (23),
with gamma rates, variable amino acid frequencies, and invariable sites. We then
used PhyML (16) for estimating a maximum-likelihood phylogeny for the given
protein evolution model and performed 100 bootstrap replications in order to
obtain bootstrap support values. Subsequently, we used neighbor-net (10, 20) to
get a better visualization of the noise in the phylogenetic signal.
RESULTS
Patients. During the observation period, 147 (82.1%) pa-
tients were treated with highly active antiretroviral therapy
(HAART), which was based on a protease inhibitor (PI; indin-
avir, saquinavir, nelfinavir, amprenavir, or ritonavir) for 117
patients and on a nonnucleoside RT inhibitor (NNRTI; nevi-
rapine, efavirenz, or delavirdine) for 30 patients. HAART was
the first-line treatment for 61 patients, and 86 had previously
undergone therapy with nucleoside analogues. HAART was
changed to different drug combinations for 85 of 117 patients
who received HAART based on PIs and for 23 of 30 patients
who received HAART based on NNRTIs to address side ef-
fects or emerging viral resistance.
The antiretroviral treatment group consisted of 18 (10.1%)
patients who received two or fewer antiretroviral drugs. One
patient received zidovudine monotherapy, and 17 were treated
with several nucleoside analogues (zidovudine, didanosine, zal-
citabine, stavudine, or lamivudine). The remaining 14 patients
(7.8%) did not receive any antiretroviral drugs.
With regard to the length of treatment, 18 patients had been
treated for 1 year, 62 patients had been treated for between
1 and 5 years, and 88 patients had been treated for 5 years.
The staging of HIV disease according to the European mod-
ification of the 1986 Centers for Disease Control and Pre-
vention staging (11) in the cohort was A for 58 patients, B
for 59 patients, and C for 57 patients. Five patients were not
classified.
HLA-associated mutations in the RT and protease. HIV RT
sequences (amino acid positions 1 to 330) were initially aligned
with the reference sequence HXB2 (27). Associations were
subsequently confirmed using the population consensus se-
quence, which was generated by assigning the most common
amino acid for each position of all sequences pooled from the
cohort. Overall, 15 associations with uncorrected P values of
less than 0.005 were found; these also had P values of less than
0.05 in the logistic regression models (Table 2). Ten of these
associations had P values of less than 0.05 after correction for
multiple testing.
We were able to confirm four of the associations that Moore
et al. reported as significant after correction for the total num-
ber of residues examined across the entire region (30): HLA-
B*51 at amino acid position 135, B*07 at position 162, A*11 at
position 166, and B*35 at position 177. We also found a num-
ber of novel HLA allele-specific associations, with four of
those associations lying outside the part of the RT sequence
analyzed by Moore et al. Seven of the mutations in the RT
sequence are located in previously defined epitopes, with six of
these being located in known epitope anchor positions.
Interestingly, six of the identified associations were negative
associations, indicating that mutations in the RT were less
likely if the patient carried that particular allele: amino acid
position 177 was negatively associated with HLA-B*35, posi-
tion 178 with HLA-B*35, position 188 with HLA-DRB1*12,
position 207 with B*15, position 277 with HLA-A*03, and
position 291 with HLA-B*27.
In the protease, we found HLA-associated mutations at
seven positions with uncorrected P values of less than 0.005;
these also had P values of less than 0.05 in the logistic regres-
sion models (Table 3). Four associations had P values of less
than 0.05 after correction for multiple testing, with three of
these associations being located in previously defined epitopes.
No negative associations were found.
For the two HLA-DRB1-associated mutations in the RT
(position 67 for HLA-DRB1*08 and position 188 for HLA-
DRB1*12), the alleles are not known to be in linkage disequi-
librium with any class I alleles which were included in the
multivariate analysis at each position.
Overall, HLA-B alleles were involved in more associations
(n  15 [68%]) than alleles from either HLA-A (n  5 [23%])
or HLA-DRB1 (n  2 [9%]).
Distribution and persistence of HLA-associated mutations.
The HLA-associated mutations that have been identified in
our patient cohort do not appear to be uniformly distributed
across the protease and RT but are more frequent in regions
known to have many epitopes. However, an analysis of the
nonrandom distribution of the HIV-1 sequence mutations
showed only a weak level of significance in the protease (P
value equal to 0.06) and none in the RT (data not shown).
For most patients, sequence mutations were consistently
found in all available sequences. In relatively few cases, the
mutations were not persistent, with the wild-type amino acid
being replaced by a variant amino acid in most cases (Tables 2
and 3). Drug therapy did not appear to influence the gain or
loss of HIV-1 sequence mutations, as most patients had
HAART composed of diverse drug combinations and yet their
mutations remained stable throughout.
Impact of HLA on drug resistance mutation pathways. Of
our patient cohort, 165 patients were treated with an NRTI
regimen containing zidovudine, stavudine, or abacavir before
the sequence used for analysis was generated. Of these pa-
tients, 72 had no TAMs reported. For TAM1 (41L, 210W, and
215F/Y), 9 patients matched the pathway and 25 showed either
one mutation too few or one too many. For TAM2 (67N, 70R,
and 219E/Q), 10 patients had matching mutations and 10 pa-
tients showed either one mutation too many or one too few.
The remaining patients showed even rarer combinations of
these mutations.
We looked for associations between either the TAM1 or the
TAM2 pathway and a particular HLA type by use of Mtreemix.
This also allowed for imperfect matches to a particular path-
way, because the software supports the analysis of complex
evolutionary scenarios. However, no significant associations
were found.
HLA-driven selection at antiretroviral drug resistance sites.
We examined all associations for our cohort, which are also
known drug resistance mutations (Table 4). Our results differ
somewhat from those of John et al. (21), who reported drug
resistance mutations at protease amino acid residues 20, 32, 36,
1268 AHLENSTIEL ET AL. CLIN. VACCINE IMMUNOL.
T
A
B
L
E
2.
H
IV
-1
sequence
m
utations
in
the
H
IV
-1
R
T
Polym
orphism
a
H
L
A
type
b
N
o.of
patients
w
ith
H
IV
-1
sequence
m
utation:
O
R
d
P
value
K
now
n
epitopes g
Persistence
h
N
ew
i
A
bsent c
Present
U
nadjusted
e
A
djusted
f
E
6x
H
L
A
-B
*40
23
11
11.08
0.00001
0.00047
B
*4001;aa
5–12
(IE
T
V
PV
K
L
)
Persistent,9;m
ultiple
pops,3;definite
change,0
Y
N
on-H
L
A
-B
*40
139
6
V
35x
H
L
A
-A
*24
19
17
3.23
0.00314

0.05
Persistent,6;m
ultiple
pops,1;definite
change,1
Y
N
on-H
L
A
-A
*24
112
31
D
67x
H
L
A
-D
R
B
1*08
1
6
13.85
0.00501

0.05
Persistent,3;m
ultiple
pops,2;definite
change,0
Y
N
on-H
L
A
-D
R
B
1*08
120
52
V
75x
H
L
A
-B
*57
6
5
9.17
0.00244

0.05
Persistent,4;m
ultiple
pops,2;definite
change,1
Y
N
on-H
L
A
-B
*57
154
14
I135x
H
L
A
-B
*51
2
22
18.40

0.00001
0.00002
B
*5101/B
51;aa
128–135
(T
A
F
T
IPSI)
Persistent,8;m
ultiple
pops,0;definite
change,1
N
N
on-H
L
A
-B
*51
97
58
E
138x
H
L
A
-A
*24
31
5
0.00026
0.00859
Persistent,7;m
ultiple
pops,0;definite
change,1
Y
N
on-H
L
A
-A
*24
143
0
S162x
H
L
A
-B
*07
21
27
6.04

0.00001
0.00004
B
7;aa
153–165
(W
K
G
PA
IF
Q
SSM
T
),
aa
153–165
(W
K
G
SPA
IF
Q
SSM
T
),
aa
156–164
(SPA
IF
Q
SSM
),aa
156–165
(SPA
IF
Q
SSM
T
)
Persistent,14;m
ultiple
pops,1;definite
change,3
N
N
on-H
L
A
-B
*07
108
23
K
166x
H
L
A
-A
*11
13
7
11.69
0.00016
0.00521
A
*1101/A
11;aa
158–166
(A
IF
Q
SSM
T
K
),aa
158–166
(SIF
Q
SSM
T
K
)
Persistent,5;m
ultiple
pops,0;definite
change,0
N
N
on-H
L
A
-A
*11
152
7
D
177x
H
L
A
-B
*35
16
18
0.14

0.00001
0.00013
B
*3501/B
35;aa
175–183
(N
PD
IV
IY
Q
Y
),aa
175–183
(H
PD
IV
IY
Q
Y
)
Persistent,10;m
ultiple
pops,0;definite
change,1
N
N
on-H
L
A
-B
*35
125
20
I178x
H
L
A
-B
*35
22
12
0.23
0.00125
0.04121
B
*3501/B
35;aa
175–183
(N
PD
IV
IY
Q
Y
),aa
175–183
(H
PD
IV
IY
Q
Y
)
Persistent,10;m
ultiple
pops,0;definite
change,1
Y
N
on-H
L
A
-B
*35
129
16
Y
188x
H
L
A
-D
R
B
1*12
5
3
0.04
0.00191

0.05
Persistent,3;m
ultiple
pops,0;definite
change,1
Y
N
on-H
L
A
-D
R
B
1*12
167
4
Q
207x
H
L
A
-B
*15
10
20
0.17
0.00003
0.00090
Persistent,8;m
ultiple
pops,1;definite
change,2
Y
N
on-H
L
A
-B
*15
111
38
K
277x
H
L
A
-A
*03
1
38
0.02

0.00001

0.00001
A
3;aa
269–277
(Q
IY
PG
IK
V
R
)
Persistent,14;m
ultiple
pops,1;definite
change,1
Y
N
on-H
L
A
-A
*03
89
51
K
277x
H
L
A
-B
*44
26
9
3.61
0.00225
0.02616
Persistent,12;m
ultiple
pops,2;definite
change,1
Y
N
on-H
L
A
-B
*44
64
80
E
291x
H
L
A
-B
*27
10
3
0.06
0.00534

0.05
Persistent,4;m
ultiple
pops,0;definite
change,0
Y
N
on-H
L
A
-B
*27
163
3
a
T
he
variant
position
relative
to
the
w
ild-type
am
ino
acid.
b
T
he
specific
H
L
A
type
for
w
hich
a
m
utation
w
as
found.
cPatients
w
ithout
the
indicated
H
IV
-1
sequence
m
utation
had
the
corresponding
w
ild-type
am
ino
acid.
d
O
R
,odds
ratio.
eT
he
unadjusted
P
value
w
as
from
the
contingency
table
and
w
as
determ
ined
by
use
of
F
isher’s
exact
test.
fT
he
adjusted
P
value
w
as
determ
ined
using
F
D
R
.
gA
ny
know
n
epitopes
for
the
H
L
A
alleles
and
their
sequences
(27).aa,am
ino
acid.
h
T
he
persistence
of
the
H
IV
-1
sequence
m
utation
in
individualpatients
at
a
m
inim
um
of
tw
o
different
tim
e
points.Persistent,alldom
inant
viralsequences
from
a
patient
w
ere
identicalat
the
different
tim
e
points;
m
ultiple
pops,dom
inantviralsequences
identified
in
a
patientw
ere
differentatthe
various
tim
e
points
w
ithouta
consistentchange
from
one
type
to
another;definite
change,the
patient’s
dom
inantviralsequence
show
ed
a
clear
sw
itch
at
this
position
from
one
am
ino
acid
to
another
am
ino
acid.Persistent,m
ultiple
pops,and
definite
change
num
bers
are
num
bers
of
patients.
iY
indicates
that
the
H
IV
-1
sequence
m
utation
is
new
;N
indicates
that
it
has
already
been
described
in
the
literature.
VOL. 14, 2007 IMPACT OF HLA AND ANTIVIRAL DRUGS ON HIV-1 1269
and 48 to have positive HLA associations. For our cohort, we
could not confirm any of these associations. John et al. also
reported the RT amino acid residues 41, 67, 70, 118, 210, and
215 to have positive HLA associations matching NRTI-associ-
ated mutations. Of these, only residue 67 was associated with
DRB1*08 in our cohort (A*10 in the work of John et al. [21]).
We also found eight new associations, five in the protease
and three in the RT. For three of the associations in the
TABLE 3. HIV-1 sequence mutations in the HIV-1 protease
Polymorphisma HLA typeb
No. of patients
with HIV-1
sequence
mutation:
ORd
P value
Known epitopesg Persistenceh Newi
Absentc Present Unadjustede Adjustedf
E35x HLA-B*44 11 24 10.91 0.00001 0.00001 B*44; aa 34–42 (EEMNLPGRW) Persistent, 14; multiple pops, 1;
definite change, 0
Y
Non-HLA-B*44 120 24
E35x HLA-A*68 11 13 4.05 0.00238 0.03922 A*6802; aa 30–38 (DTVLEDI
NL), aa 30–38 (DTVLEEM
NL), aa 30–38 (DTVLEE
WNL)
Persistent, 7; multiple pops, 0;
definite change, 0
Y
Non-HLA-A*68 120 35
N37x HLA-B*44 9 26 6.15 0.00001 0.00022 B*44; aa 34–42 (EEMNLPGRW) Persistent, 11; multiple pops, 3;
definite change, 1
Y
Non-HLA-B*44 98 46
I54x HLA-B*57 5 6 7.57 0.00285 0.05 Persistent, 4; multiple pops, 0;
definite change, 3
Y
Non-HLA-B*57 145 23
V82x HLA-B*57 5 6 6.55 0.00499 0.05 Persistent, 5; multiple pops, 1;
definite change, 1
Y
Non-HLA-B*57 142 26
Q92x HLA-B*15 22 8 17.70 0.00003 0.00099 Persistent, 10; multiple pops, 1;
definite change, 0
Y
Non-HLA-B*15 146 3
I93x HLA-B*15 11 19 3.63 0.00184 0.05 Persistent, 10; multiple pops, 0;
definite change, 1
Y
Non-HLA-B*15 101 48
a The variant position relative to the wild-type amino acid.
b The specific HLA type for which a mutation was found.
c Patients without the indicated HIV-1 sequence mutation had the corresponding wild-type amino acid.
d OR, odds ratio.
e The unadjusted P value was from the contingency table and was determined by use of Fisher’s exact test.
f The adjusted P value was determined using FDR.
g Any known epitopes for the HLA alleles and their sequences (27). aa, amino acid.
h The persistence of the HIV-1 sequence mutation in individual patients at a minimum of two different time points. Persistent, all dominant viral sequences from
a patient were identical at the different time points; multiple pops, dominant viral sequences identified in a patient were different at the various time points without
a consistent change from one type to another; definite change, the patient’s dominant viral sequence showed a clear switch at this position from one amino acid to
another amino acid. Persistent, multiple pops, and definite change numbers are numbers of patients.
i Y indicates that the HIV-1 sequence mutation is new; N indicates that it has already been described in the literature.
TABLE 4. HIV-1 sequence mutations at positions which are also known drug resistance mutations and numbers of patients exhibiting the
indicated HLA type who received the indicated drug type
Drug or resistance type Polymorphisma HLA typeb
No. of patients with
HIV-1 sequence
mutation:
No. of patients (%)
who received drugs New
d
Absentc Present
Tipranavir-ritonavir PRO-E35x HLA-B*44 11 24 0 of 24 (0) Y
Non-HLA-B*44 120 24 0 of 155 (0)
PRO-E35x HLA-A*68 11 13 0 of 35 (0) Y
Non-HLA-A*68 120 35 0 of 144 (0)
Many currently used PIs PRO-I54x HLA-B*57 5 6 10 of 11 (90.9) Y
Non-HLA-B*57 145 23 117 of 168 (69.6)
PRO-V82x HLA-B*57 5 6 10 of 11 (90.9) Y
Non-HLA-B*57 142 26 117 of 168 (69.6)
Atazanavir PRO-Q92x HLA-B*15 22 8 0 of 30 (0) Y
Non-HLA-B*15 146 3 0 of 149 (0)
Multi-NRTI resistance RT-D67x HLA-DRB1*08 1 6 7 of 7 (100) Y
Non-HLA-DRB1*08 120 52 158 of 172 (91.8)
RT-V75x HLA-B*57 6 5 11 of 11 (100) Y
Non-HLA-B*57 154 14 154 of 168 (91.6)
NNRTIs RT-Y188x HLA-DRB1*12 5 3 5 of 8 (62.5) Y
Non-HLA-DRB1*12 167 4 84 of 171 (49.1)
a HIV-1 sequence mutation in the protease or RT.
b Specific HLA type for which the mutation was found.
c Patients without the indicated HIV-1 sequence mutation had the corresponding wild-type amino acid.
d Y indicates that the association is new; N indicates that it has already been described in the literature.
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protease (residue 35 for A*68 and B*44 and residue 92 for
B*15), none of the patients in our cohort had ever been treated
with the relevant antiviral therapy (tipranavir-ritonavir or
atazanavir). In contrast, for the remaining five associations
(residues 54 and 82 in the protease and residues 67, 75, and 188
in the RT), most patients had been treated with the relevant
antiviral therapy. These residues are associated with resistance
against most currently available PIs, NNRTIs, and multinucleo-
side and -nucleotide RT inhibitors (multi-NRTIs). However,
statistically significant differences for patients taking these
drugs could not be found between individuals with or without
the HLA allele.
We observed that HCV-coinfected patients were less likely
to have received antiretroviral therapy which included PIs.
Phylogenetic analysis. The shape of the maximum-likeli-
hood phylogeny is almost star-like: the sequence diversity
within clusters is higher than the diversity between clusters.
Another indicator for the star likeness is the low bootstrap
support for all branches in the interior of the phylogeny. The
resulting neighbor-net network (Fig. 1) shows a good deal of
netting in the center of the phylogeny and rejects a clustering
into distinct groups. Hence, the neighbor-net method also sug-
gests a star-like shape for the phylogeny. Given that the se-
quences evolved along a star-like phylogeny, we can rule out
founder effects or other artifacts due to a shared evolutionary
history.
DISCUSSION
Selection of the dominant HIV-1 population among the viral
quasispecies is likely to reflect the combined effects of viral
adaptation to the host’s immune response and antiretroviral
drugs. MHC class I alleles have been described as affecting the
evolution of the HIV-1 sequence on the population level in a
single previous cohort from Western Australia (21, 30). We
were interested in examining whether these findings could be
confirmed for our Western European cohort.
Four out of a total of 12 significant associations previously
reported for the RT were confirmed for our cohort, all of
which corresponded to known epitopes (Table 2). Moreover,
we describe 11 new associations, with 4 of these lying outside
the region of the RT analyzed previously (30). Several of these
associations also correspond to known T-cell epitopes.
The identified CTL escape mutations, for which known
epitopes exist, do not consistently lie in known anchor posi-
tions. Due to the complex pathway by which an epitope is
processed before being displayed on the cell surface by the
HLA molecule and the incompletely understood nature of
FIG. 1. Neighbor-net network of the cohort illustrating a star-like shape and a high level of netting in the center of the phylogeny.
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T-cell receptor binding and T-cell activation, HIV-1 sequence
mutations in nonanchor positions could very well still have a
negative impact on the recognition of such epitopes and hence
be beneficial for the virus.
These data support the hypothesis that the associations
found are indeed epitopes targeted by CTLs and that contin-
uous pressure by CTL responses leads to the selection of sur-
vival strains that have mutations in these regions. The fact that
we cannot reproduce all associations described in the previous
publications and that we found a number of additional associ-
ations may be due to several reasons: the first cohort consisted
of patients from Western Australia, whereas our patients are
mainly Caucasians from Germany. Thus, the available HLAs
may differ, and the levels of access to and types of antiviral
drugs may be different. However, the fact that we were able to
confirm a number of associations despite these differences
proves that our main conclusions, although affected by local
factors, are generally true. Furthermore, HLA-associated mu-
tations, once acquired, were stable and found in later viral
isolates from the same patient. This supports the hypothesis
that the continuing selection pressure by T-cell recognition
prevents the virus from reverting back despite changes in the
antiviral drug regimen.
MHC class I-dependent CTL responses shape the viral se-
quence by directly killing infected cells that present the right
epitope in their HLA molecules. So far, the impact of MHC
class alleles II on viral evolution has been studied only for a
small patient group. Harcourt et al. (18) described HIV se-
quence variation in the p24 GAG epitope of HLA-DR1. Our
data from a large patient cohort support their observation of a
role of MHC class II alleles and CD4 T-cell responses in the
evolution of the HIV-1 sequence. We found two associations in
the RT region, also demonstrating that even class II alleles can
exert selection pressure on viral sequences.
We also studied the effect of MHC class I and class II on the
evolution of the full-length protease sequence. Interestingly,
we did not find any of the associations which were described
for the Western Australian cohort (21). The underlying reason
for this is unclear. However, since most patients in our cohort
and the Western Australian cohort were undergoing drug
treatment, it is possible that the type, time point, and length of
use of certain PIs may have affected the results from our study
as well those from the previous studies. Nevertheless, three
associations were found within previously described epitopes
for the same HLA allele, and four associations remained sig-
nificant after correction for multiple testing, supporting the
validity of the associations reported.
Although we were not able to confirm statistically the exis-
tence of “hot spots,” as the effect reached only a weak level of
statistical significance (P value equal to 0.06), it appears that
certain regions in the RT and protease are targeted by a
greater number of epitopes and therefore CTLs, thus driving
viral evolution in this region.
Recently, a study by Kiepiela et al. reported that the relative
contribution of HLA-B alleles outweighs the contribution of
HLA-A alleles in influencing HIV disease outcome (25). This
is also reflected in our results, as more significant associations
were found with HLA-B alleles (n  15 [68%]) than with
HLA-A alleles (n  5 [23%]) or HLA-DRB1 alleles (n  2
[9%]).
For most patients, HLA-associated HIV-1 sequence muta-
tions were consistently found for all sequences from that pa-
tient, while only relatively few cases had HLA-associated mu-
tations that were not stable. These changes were generally
from a wild-type amino acid to the variant amino acid in the
subsequent sample. This observation is consistent with other
studies showing that CTL escape mutations develop soon after
infection (24).
We also analyzed whether these HLA-associated mutations
were influenced by drug therapy and found that the impact of
drug therapy on the associations for our patient cohort was not
statistically significant. In some cases, patients in the cohort
had not received a particular drug treatment (tipranavir or
atazanavir) yet showed HLA-associated mutations at positions
where known mutations providing resistance to these particu-
lar drugs can also occur. As tipranavir and atazanavir were first
approved for antiviral therapy shortly after our patients’ viral
sequences were acquired, it is not possible for these patients to
have been infected with an already resistant viral strain. This
indicates either that these mutations have become locked in
our population, so that the virus cannot revert back, or that
HLA-driven selection of mutations may predispose some pa-
tients to the development of some drug resistance mutations.
In order to optimize the therapy of patients carrying particular
HLA types, the choice of future therapy regimens should take
into account the fact that some patients are more likely to
develop particular HLA-associated mutations, which coexist at
residues of drug resistance mutations. This consideration could
be made for positions in the protease that are linked to specific
drugs (tipranavir and atazanavir) but not to the majority of PIs,
multi-NRTIs, or NNRTIs.
In summary, we were able to confirm immune-driven selec-
tion pressure not only by MHC class I alleles but also by MHC
class II alleles on the development of escape mutations at a
population level. Further, we have described a number of
HLA-associated mutations in the RT as well as protease and,
finally, have analyzed their possible impact on the success of
antiviral drug treatment.
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